The following influenza reagents are now available on the NIBSC website:
Influenza Virus Infectious X-283A 42420 ExE1
Influenza Virus Infectious X-285A 42440 ExE1
Influenza Virus Infectious X-285 42430 ExE1
Welcome to EDUFLUVAC, a collaborative project funded under the European Commission (EC) 7th Framework Programme (FP7) and coordinated by the European Vaccine Initiative (EVI). The four-year project was initiated in November 2013 and has an overall budget of € 4.6 million. The project is the joint effort of leading European experts from academia and industry with unique and specific technological expertise in vaccine development.
The EDUFLUVAC project aims at developing a “universal” influenza vaccine that can provide longer-lasting and broader protection against multiple strains of influenza virus. EDUFLUVAC will provide the proof of principle of a novel influenza vaccine concept that does not have to be updated annually, does not have to be manufactured on an annual basis, and will not require an annual vaccination campaign. It will also provide an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, could manufacture rapidly high quantities of vaccine.
The aimed level of broad protection will reduce the burden of disease that influenza imposes across Europe and other regions on an annual basis.
Group picture taken at the EDUFLUVAC Kick-Off Meeting in Heidelberg on 20 November 2013.
This project has been funded with support from the European Commission under Grant agreement no: 602640
This website reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
VAC2VAC is a wide ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non animal methods.
The initiative that started on 1 March 2016 aims to provide the data to support the ‘Consistency Approach’ for quality control of established vaccines. More information on the project and on the participants can now be found under the following link: www.vac2vac.eu.